Adjacent cell marking method and application thereof
Cell labeling is performed by enzymatic activation of methylene benzenequinone intermediates generated by methylene benzenequinone probe, achieving efficient cell marking and gene expression analysis in cells and tissues, solving the short marking radius and efficiency in the prior art Low problem.
Patent Information
- Application Number
- CN202310487623.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-04
- Publication Date
- 2024-11-08
AI Technical Summary
Existing cell marking methods have shortcomings in labeling radius and efficiency, especially in cell markings in non-direct contact cells and tissues, making it difficult to achieve efficient cell proximity marking.
The methylene benzenequinone intermediate generated by the enzyme-activated methylene benzenequinone probe is used for covalent labeling, and the enzyme is covalently linked to the nucleophilic residues of cell surface proteins can be achieved to achieve adjacent cell types, and Gene expression analysis was performed in combination with flow cytometry and RNA sequencing.
Achieve large marker radius (about 1-10 μm) and efficient cell marker in cells and tissues, solving the problems of short marker radius and low efficiency, enabling efficient marker in non-direct contact cells and tissues, and comprehensively analyse specific Gene expression of cell type.
Smart Images

Figure CN118910234A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a neighboring cell labeling method and application thereof. Background Art
[0002] In multicellular organisms, different cells are spatially organized to form functional tissues and organs. Cells can exchange biochemical signals with each other through direct cell-cell contact or diffusible molecules. In order to study the biological functions of cellular spatial organization, two types of proximity labeling strategies have been developed to label, separate and analyze cells around a specific cell type. Among these methods, LIPSITC (G. Pasqual, A. Chudnovskiy, JMJ Tas, M. Agudelo, LDSchweitzer, A. Cui, N. Hacohen, GD Victora, Nature) is the most popular. 2018, 553, 496–500.), EXCELL (Y. Ge, L. Chen, S. Liu, J. Zhao, H. Zhang, PRChen, J. Am. Chem. Soc. 2019, 141, 1833–1837), PUP-IT (Q. Liu, J. Zheng, W. Sun, Y. Huo, L. Zhang, P. Hao, H. Wang, M. Zhuang, Nat. Methods 2018, 15, 715–722) and FucoID (Z. Liu, JPLi, M. Chen, M. Wu, Y. Shi, W. Li, JRTeijaro, P. Wu, Cell 2020, 183, 1117-1133.e19.) are represented by methods that use exogenous enzymes expressed on the surface of specific cells to catalyze the connection of biotin-containing substrate probes to surface receptors of nearby target cells. Since these methods rely on enzymatic reactions at the cell-cell contact interface, their labeling radius is usually limited to within 10 nm, so only cell interactions with very high intensity will be labeled.Another type of method is μMAP (JB Geri, JV Oakley, T. Reyes-Robles, T. Wang, SJ McCarver, CH White, FP Rodriguez-Rivera, DL Parker, ECH Tett, OO Fadeyi, RCO Slund, DWC MacMillan, Science. 2020, 367, 1091–1097.), PhoTag (RCO Slund, T. Reyes-Robles, CH White, JH Tomlinson, KA Crotty, EP Bowman, D. Chang, VM Peterson, L. Li, S. Frutos, M. Vila -Perelló, D. Vlerick, K. Cromie, DH Perlman, S. Ingale, SDO Hara, LR Roberts, G. Piizzi, ECHett, DJ Hazuda, OO Fadeyi, Nat. Chem. Biol. 2022, 18, 850–858.) and PhoXCELL (H. Liu, H. Luo, Q. Xue, S. Qin, S. Qiu, S. Liu, J. Lin, JP Li, PR Chen, J. Am. Chem. Soc. 2022, 144, 5517–5526.) use photocatalytic chemistry to produce free radicals such as carbenes, phenol radicals or singlet oxygen around specific target cells to mark cells in the immune synapse. Because these substances are so active that they are easily quenched in the cell environment, the labeling radius of this type of method is usually between 50 and 250nm (JV Oakley, BF Buksh, DF Fernández, DG Oblinsky, CP Seath, JB Geri, GD Scholes, DWC MacMillan, Proc. Natl. Acad. Sci. USA 2022, 119, e2203027119.). In fact, due to the short labeling radius, these intermediates are often used in proximity labeling at the protein interaction level (Y. Zhou, P. Zou, Curr. Opin. Chem. Biol. 2021, 60, 30–38.). In addition, these methods for labeling cell communication in tissue samples are often interfered with by extracellular matrix proteins. Summary of the invention
[0003] In order to solve the above problems, the present invention provides a cell labeling technology QMID (quinone-methide-assisted identification of cell spatial organization).
[0004] The cell labeling method provided by the present invention is to covalently label cells with quinone methide (QM) intermediates generated by enzyme-activated quinone methide probes, that is, to achieve in situ labeling of cells. This method is named QMID.
[0005] Among them, the quinone methide (QM) intermediate is covalently linked to the nucleophilic residues of cell surface proteins;
[0006] The cells are cells that are adjacent to a specific cell type (referring to any cell type that the antibody can recognize).
[0007] The methylene benzoquinone probe has the following structural units:
[0008]
[0009] In one embodiment of the present invention, the structural formula of the methylene benzoquinone probe is as shown in Formula I:
[0010]
[0011] In formula I, R1 represents H, C1-C3 alkyl (specifically, methyl);
[0012] R2 can be selected from: β-galactose residue, glutamic acid residue, sialic acid residue, fucose residue, etc.;
[0013] Biotin indicates
[0014] In one embodiment of the present invention, the structural formula of the methylene benzoquinone probe is as follows:
[0015]
[0016] In another embodiment of the present invention, the structural formula of the methylene benzoquinone probe is as follows:
[0017]
[0018] According to the substituent R2 in the methylene benzoquinone probe, a corresponding enzyme is selected to remove the R2 group;
[0019] In the methylene benzoquinone probe, R2 is a β-galactose residue, and the enzyme is β-galactosidase (βGal);
[0020] The enzyme is also linked to an antibody that binds to a specific cell type for targeting the specific cell type.
[0021] After labeling the cells in situ, the above method may further include separating the labeled cells using a flow cytometer and combining it with RNA sequencing or single-cell RNA sequencing to achieve a comprehensive analysis of the gene expression of neighboring cells of specific cells.
[0022] The application of the methylene benzoquinone probe represented by the above formula I in the QMID method also falls within the protection scope of the present invention.
[0023] The application of the QMID method in proximity labeling of cells that are not in direct contact and proximity labeling of cells in tissues also falls within the protection scope of the present invention.
[0024] The present invention also provides a method for analyzing gene expression of cells adjacent to a specific cell.
[0025] The method for analyzing gene expression of neighboring cells of a specific cell provided by the present invention comprises the following steps:
[0026] 1) Incubate the cell system to be analyzed with the enzyme to modify the enzyme on the surface of specific cells;
[0027] 2) adding a methylene benzoquinone probe to the system obtained in step 1) to complete labeling;
[0028] 3) Analyze cells using flow cytometry or confocal fluorescence imaging to confirm the labeling effect of neighboring cells.
[0029] Target specific RNAs and proteins using FISH or immunofluorescence, and analyze gene expression in neighboring cells using flow cytometry.
[0030] The examples of the present invention have been experimentally demonstrated that QMID can achieve cell proximity labeling in cultured cells and tissue samples, and can be combined with flow cytometry to perform RNA sequencing or single-cell RNA sequencing analysis.
[0031] The QMID method of the present invention displays a specific deprotection enzyme on the cell surface to deprotect the probe substrate and generate a quinone methide (QM) intermediate. QM has a strong electrophilicity and is used as a labeling active intermediate to covalently label cells adjacent to a specific cell type. QMID realizes the proximity labeling of non-direct contact cells and the proximity labeling of cells in tissues that are difficult to achieve with existing methods. The labeled cells can be analyzed using a flow cytometer or confocal fluorescence imaging. RNA sequencing or single-cell RNA sequencing after sorting the labeled cells can comprehensively analyze the gene expression of cells adjacent to specific types of cells. QMID (the labeling radius of QMID is approximately 1-10 μm) solves the problems of short labeling radius and low labeling efficiency in tissues in existing methods, and realizes efficient cell proximity labeling in cells and tissues. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 The chemical synthesis route of gFQM-biotin and gFMeQM-biotin in Example 1 of the present invention is shown in FIG.
[0033] Figure 2 This is the protein purification characterization of ZHER-βGal in Example 2 of the present invention.
[0034] Figure 3 Design and characterization of QMID probes. (A) Labeling mechanism of enzyme-activated QMs for cellular-scale proximity labeling. (B) Chemical formulas of gFQM-biotin and gFMeQM-biotin. (C) LC-MS analysis of enzymatic activation of gFQM-biotin and gFMeQM-biotin mediated by βGal. (D) Immunoblotting characterization of HEK293T cell lysates labeled by gFQM-biotin and gFMeQM-biotin in the presence and absence of βGal. (E) Flow cytometry characterization of HEK293T cell labeling by gFQM-biotin and gFMeQM-biotin in the presence and absence of βGal. (F) Selective labeling of HER2+ cells by ZHER-βGal using ONPG. (G) LC-MS analysis of HER2+ cells pre-incubated with PBS / βGal / ZHER-βGal by gFQM-biotin and gFMeQM-biotin + Flow cytometric characterization of markers of WT / WT MDA cells.
[0035] Figure 4 QMID is used for cell-scale proximity labeling in co-culture systems. (A) QMID labeling process in cell suspension. (B) Effects of gFQM-biotin and gFMeQM-biotin on HER2 cells with or without prior incubation with ZHER-βGal.+ Flow cytometric characterization of the mixed suspension of MDA cells and WTMDA cells. (C,D) gFQM-biotin (C) and gFMeQM-biotin (D) for HER2 + Confocal imaging of the co-culture system of MDA cells and WT MDA cells using QMID labeling. Scale bar, 20 μm. (E, F) Effects of gFQM-biotin (E) and gFMeQM-biotin (F) on HER2 + The co-culture system of MDA cells and WT MDA cells was characterized by flow cytometry using QMID labeling.
[0036] Figure 5 QMID for cell-scale proximity labeling of mouse spleen sections. (A) Schematic diagram of QMID labeling of mouse spleen sections using a combination of primary antibody-biotin conjugate and streptavidin-βGal conjugate. (B,C) Confocal imaging characterization of QMID labeling of neighboring cells of CD8+ T cells (B) and CD4+ T cells (C). (D) Flow cytometry characterization of QMID labeling of neighboring cells of CD8+ T cells and CD4+ T cells.
[0037] Figure 6 QMID analysis of neighboring cell maps of mouse spleen T cells. (A) UMAP analysis of neighboring cells of CD8+T cells and CD4+T cells in mouse spleen sections. (B) Stacked bar chart of normalized relative proportions of different types of cells. (C) Heat map of genes with significantly different expression levels in mature dendritic cells adjacent to CD8+T cells and CD4+T cells. (D) GSEA shows that lipid degradation processes and WNT signaling pathways are significantly upregulated in mature dendritic cells adjacent to CD8+T cells. DETAILED DESCRIPTION
[0038] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0039] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0040] Example 1. Synthesis of galactosidase-based QMID probes gFQM-biotin and gFMeQM-biotin
[0041] 1 g of 5-nitrosalicylic aldehyde and 2.46 g of 2,3,4,6-tetraacetoxy-α-D-pyranose bromide were dissolved in 80 mL of acetonitrile, 1.39 g of silver oxide was added and stirred evenly, and the reaction was carried out at room temperature for 1 h. After the reaction, the silver oxide was filtered off and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography (petroleum ether-ethyl acetate, 100%: 0 to 50%: 50%) to obtain white solid compound 1 (2.65 g, 89%).
[0042] 2.58g of compound 1 was dissolved in 80mL of tetrahydrofuran and 20mL of methanol, 78.7mg of sodium borohydride was added, and the reaction was carried out at room temperature for 30min. After the reaction was completed, the solvent was removed by rotary evaporation, 100mL of 1M hydrochloric acid was added, and 70mL of ethyl acetate was used for three extractions. The organic phases were combined and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in sequence. The obtained organic phase was dried over anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The obtained crude product was purified by column chromatography (petroleum ether-ethyl acetate, 100%: 0 to 50%: 50%) to obtain white solid compound 2 (2.49g, 96%).
[0043] 1.63g of compound 2 was dissolved in 50mL of dichloromethane, 631mg of diethylamino sulfur trifluoride was added, and the reaction was allowed to react at room temperature overnight. After the reaction was completed, 50ml of ice water was added and extracted three times with 50mL of dichloromethane, the organic phases were combined and washed successively with saturated sodium bicarbonate solution and saturated sodium chloride solution, the obtained organic phase was dried with anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The obtained crude product was purified by column chromatography (petroleum ether-ethyl acetate, 100%: 0 to 60%: 40%) to obtain white solid compound 3 (1.13g, 69%).
[0044] 1 g of compound 3 was dissolved in 70 mL of dichloromethane, and 1.3 g of zinc powder and 570 μL of acetic acid were added at 0 ° C. The reaction was allowed to warm up naturally overnight. After the reaction was completed, the zinc powder was filtered off, the solvent was removed by rotary evaporation, and the mixture was redissolved in 100 mL of ethyl acetate, washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in sequence, and the obtained organic phase was dried over anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The obtained crude product 4 was used directly in the subsequent steps.
[0045] The compound 4 obtained in the previous step was dissolved in 40 mL of N, N-dimethylformamide, and 305 mg of biotin, 185 mg of 1-hydroxybenzotriazole, 262 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 300 μL of N, N-diisopropylethylamine were added, and the reaction was carried out at 60°C for 3 h. After the reaction was completed, 10 mL of 1M hydrochloric acid and 40 mL of water were added for dilution, and 30 mL of ethyl acetate was used for three extractions. The organic phases were combined and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in sequence, and the obtained organic phase was dried over anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The obtained crude product was purified by column chromatography (dichloromethane-methanol, 100%: 0 to 95%: 5%) to obtain a white solid compound 5 (273 mg, 34%).
[0046] 185 mg of compound 5 was dissolved in 12 mL of methanol, and 24 mg of sodium methoxide (30% methanol solution) was added, and the reaction was carried out at room temperature for 2 h. After the reaction, hydrogen-type ion exchange resin was added to adjust the system to neutrality, the resin was filtered off, and the solvent was removed by rotary evaporation. The crude product was purified by high performance liquid chromatography (water-acetonitrile, 95%:5% to 0%:100%) to obtain a white solid compound gFQM-biotin (111 mg, 79%). The complete synthetic route is attached. Figure 1 .
[0047] 1.85 g of 2-hydroxy-5-nitroacetophenone and 4.2 g of 2,3,4,6-tetraacetoxy-α-D-pyranose bromide were dissolved in 120 mL of acetonitrile, 2.37 g of silver oxide was added and stirred evenly, and the reaction was allowed to proceed overnight at room temperature. After the reaction, the silver oxide was filtered off and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography (petroleum ether-ethyl acetate, 100%:0% to 50%:50%) to obtain compound 6 (5.09 g, 98%) as a white solid.
[0048] 4.94g of compound 6 was dissolved in 120mL of tetrahydrofuran and 30mL of isopropanol, 179mg of sodium borohydride was added at 0°C, the temperature was naturally restored, and the reaction was carried out at room temperature for 3h. After the reaction was completed, the solvent was removed by rotary evaporation, 150mL of 1M hydrochloric acid was added, and 150mL of ethyl acetate was used for three extractions. The organic phases were combined and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in sequence. The obtained organic phase was dried over anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The crude product was purified by column chromatography (petroleum ether-ethyl acetate, 100%: 0% to 50%: 50%) to obtain white solid compound 7 (3.08g, 62%).
[0049] 2.5g of compound 7 was dissolved in 100mL of dichloromethane, 942mg of diethylamino sulfur trifluoride was added, and the reaction was allowed to react at room temperature overnight. After the reaction was completed, 100mL of ice water was added and extracted three times with 100mL of dichloromethane, the organic phases were combined and washed successively with saturated sodium bicarbonate solution and saturated sodium chloride solution, the obtained organic phase was dried with anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The obtained crude product was purified by column chromatography (petroleum ether-ethyl acetate, 100%: 0% to 60%: 40%) to obtain white solid compound 8 (1.93g, 77%).
[0050] 1.5 g of compound 8 was dissolved in 100 mL of dichloromethane, and 1.9 g of zinc powder and 850 μL of acetic acid were added at 0°C, and the reaction was allowed to warm up naturally overnight. After the reaction was completed, the zinc powder was filtered off, the solvent was removed by rotary evaporation, and the mixture was redissolved in 150 mL of ethyl acetate, washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in sequence, and the obtained organic phase was dried over anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The obtained crude product 9 was used directly in the subsequent steps.
[0051] The compound 9 obtained in the previous step was dissolved in 70 mL of N, N-dimethylformamide, and 782 mg of biotin, 472 mg of 1-hydroxybenzotriazole, 669 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 775 μL of N, N-diisopropylethylamine were added, and the mixture was reacted at 60°C for 6 h. After the reaction was completed, 50 mL of 1M hydrochloric acid was added for dilution, and the mixture was extracted three times with 80 mL of ethyl acetate. The organic phases were combined and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in sequence, and the obtained organic phase was dried with anhydrous sodium sulfate and the solvent was removed by rotary evaporation again. The obtained crude product was purified by column chromatography (dichloromethane-methanol, 100%:0% to 95%:5%) to obtain a white solid compound 10 (1.87 g, 72%).
[0052] 1.5 g of compound 10 was dissolved in 100 mL of methanol, and 190 mg of sodium methoxide (30% methanol solution) was added, and the reaction was carried out at room temperature for 2 h. After the reaction, hydrogen-type ion exchange resin was added to adjust the system to neutrality, the resin was filtered off, and the solvent was removed by rotary evaporation. The crude product was purified by high performance liquid chromatography (water-acetonitrile, 95%:5% to 0%:100%) to obtain a white solid compound gFMeQM-biotin (978 mg, 85%). The complete synthetic route is attached. Figure 1 .
[0053] Example 2. Expression and purification of ZHER-βGal
[0054] Plasmid construction. The βGal sequence was obtained by PCR from the E. coli genome. The ZHER sequence was obtained by PCR from a plasmid containing the ZHER fragment.
[0055] The PCR primers for amplification of the βGal sequence were: 5′-CTCGAGTGCGGCCGCAAGCTTTTTTTGACACCAGACCAACTGGTAAT-3′ and 5′-GCACCAAGGGAAGCACAAGCGGAAGC GGCAAACCCGGAAGCGGAGACGGAAGCACCAAGGGCATGATTACGGATTCACT GGCCG-3′;
[0056] The PCR primers for ZHER sequence amplification were: 5′-ATGGGTCGCGGATCCG AATTCATGGTGGATAACAAATTTAACAAAGAAATGC-3′ and 5′-TGCTTCCCT TGGTGCTGCCTTCTCCGCTTCCAGGCTTTCCGCTGCCGCTGGTGCTGCCGCCTTT CGGCGCCTGCGC-3′
[0057] Subsequently, the βGal sequence fragment and the ZHER sequence fragment were homologously recombined into the pET28a plasmid. The homologous recombination product was transformed into DH5α competent cells. Single clone colonies were picked, plasmids were extracted, and the plasmid sequences were sequenced to verify.
[0058] Transformation: Take 2 μL of the correct plasmid and transfer it into 50 μL of E. coli BL21 (DE3) competent cells, incubate on ice for 20 minutes, heat shock at 42°C for 1 minute, and then immediately incubate on ice for 2 minutes. Add 500 μL of antibiotic-free LB medium and shake and culture at 37°C for 1 hour. Then spread the bacterial solution evenly on an LB plate containing 100 μg / mL of kanamycin and culture it in a 37°C incubator overnight.
[0059] Pick-point expansion culture: Pick a single clone on the plate and place it in 4 mL of LB medium containing 50 μg / mL kanamycin, and culture it at 37°C with shaking overnight; transfer the overnight culture liquid into 1 L LB medium (containing 50 μg / mL kanamycin), and culture it at 37°C, 220 rpm / min, for 3-5 hours.
[0060] Induction: When the OD600 of the bacterial solution reaches 0.6-0.8, add IPTG for induction (final concentration is 500 μM) and culture at 16°C, 180 rpm / min for 20 h.
[0061] Purification: 4500g, 20℃ centrifugation for 10 min to remove the supernatant and collect the induced Escherichia coli; resuspend the precipitate in PBS solution; ultrasonically disrupt it in an ice-water mixed bath; centrifuge at 13000g, 4℃ for 30 min to collect the supernatant; place all the supernatant in a pre-treated nickel column (rinse with binding solution for 5 column volumes, 10mM imidazole in / L PBS); then rinse with 10 column volumes of cleaning solution (30mM imidazole / L PBS); finally, the target protein is eluted with elution solution (250mM imidazole / L PBS); finally, ultrafiltration is performed three times using a 30kDa ultrafiltration tube (4500g, 20min).
[0062] Identification: The eluted target protein was subjected to polyacrylamide gel electrophoresis (10% SDS-PAGE) to detect whether the molecular weight was correct.
[0063] Quantification: Use NanoDrop spectrophotometer to test the absorbance of the protein solution at 280 nm to obtain the concentration of the purified protein solution.
[0064] The protein sequence and purification results of ZHER-βGal are shown in Figure 2 shown.
[0065] ZHER-βGal sequence
[0066] MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFMVDNKFNKEMRNAYWEIALLPNLNNQQKRA
[0067] FIRSLYDDPSQSANLLAEAKKLNDAQAPKGGSTSGSGKPGSGEGSTKGSTSSGGKPGSGDGSTKGMITDS
[0068] LAVVLQRRDWENPGVTQLNRLAAHPFASWRNSEEARTDRPSQQLRSLNGEWRFAWFPAPEAVPESWL
[0069] ECDLPEADTVVVPSNWQMHGYDAPIYTNVTYPITVNPPFVPTENPTGCYSLTFNVDESWLQEGQTRIIFD
[0070] GVNSAFHLWCNGRWVGYGQDSRLPSEFDLSAFLRAGENRLAVMVLRWSDGSYLEDQDMWRMSGIFR
[0071] DVSLLHKPTTQISDFHVATRFNDDFSRAVLEAEVQMCGELRDYLRVTVSLWQGETQVASGTAPFGGEIID
[0072] ERGGYADRVTLRLNVENPKLWSAEIPNLYRAVVELHTADGTLIEAEACDVGFREVRIENGLLLLNGKPLL
[0073] IRGVNRHEHHPLHGQVMDEQTMVQDILLMKQNNFNAVRCSHYPNHPLWYTLCDRYGLYVVDEANIET
[0074] HGMVPMNRLTDDPRWLPAMSERVTRMVQRDRNHPSVIIWSLGNESGHGANHDALYRWIKSVDPSRPV
[0075] QYEGGGADTTATDIICPMYARVDEDQPFPAVPKWSIKKWLSLPGETRPLILCEYAHAMGNSLGGFAKYW
[0076] QAFRQYPRLQGGFVWDWVDQSLIKYDENGNPWSAYGGDFGDTPNDRQFCMNGLVFADRTPHPALTEA
[0077] KHQQQFFQFRLSGQTIEVTSEYLFRHSDNELLHWMVALDGKPLASGEVPLDVAPQGKQLIELPELPQPES
[0078] AGQLWLTVRVVQPNATAWSEAGHISAWQQWRLAENLSVTLPAASHAIPHLTTSEMDFCIELGNKRWQF
[0079] NRQSGFLSQMWIGDKKQLLTPLRDQFTRAPLDNDIGVSEATRIDPNAWVERWKAAGHYQAEAALLQCT
[0080] ADTLADAVLITTAHAWQHQGKTLFISRKTYRIDGSGQMAITVDVEVASDTPHPARIGLNCQLAQVAERV
[0081] NWLGLGPQENYPDRLTAACFDRWDLPLSDMYTPYVFPSENGLRCGTRELNYGPHQWRGDFQFNISRYS
[0082] QQQLMETSHRHLLHAEEGTWLNIDGFHMGIGGDDSWSPSVSAEFQLSAGRYHYQLVWCQKKLAAALE
[0083] HHHHHH
[0084] Example 3. Characterization of QMID probe
[0085] 1. Detect the deprotection of gFQM-biotin and gFMeQM-biotin catalyzed by βGal.
[0086] (1) Dissolve gFQM-biotin and gFMeQM-biotin in deionized water to a final concentration of 50 μM.
[0087] (2) Take 1 mL of each sample into a 1.5 mL eppendorf tube, add βGal (purchased from Abcam, catalog number ab79449, final concentration 5 μg / mL), incubate at 37°C for 30 min, and then detect using LCMS.
[0088] 2. Detect βGal-catalyzed gFQM-biotin and gFMeQM-biotin to label proteins.
[0089] (1) Add gFQM-biotin or gFMeQM-biotin (final concentration: 10 μM) and βGal (purchased from Abcam, catalog number ab79449, final concentration: 5 μg / mL) to HEK293T cell lysate at a concentration of 1 mg / mL and incubate at 37°C for 30 min.
[0090] (2) The lysate was subjected to SDS-PAGE analysis and transferred to a membrane, and blocked with TBST containing 10% skimmed milk powder at room temperature for 1 h.
[0091] (3) Discard the solution and place the membrane in TBST containing streptavidin-horseradish peroxidase (purchased from Bio-Time, catalog number A0303, 1:2000 dilution) and incubate at room temperature for 1 h.
[0092] (4) Wash with TBST three times, 5 min each time.
[0093] (5) Chemiluminescent imaging of the membrane was performed using Tanon.
[0094] 3. Detect βGal-catalyzed gFQM-biotin and gFMeQM-biotin to label the cell surface.
[0095] (1) Add gFQM-biotin or gFMeQM-biotin (final concentration of 50 μM) and βGal (purchased from Abcam, catalog number ab79449, final concentration of 2 μg / mL) to the HEK293T cell suspension and incubate at 37°C for 30 min.
[0096] (2) After labeling, wash the cells three times with PBS solution.
[0097] (3) The cells were resuspended in PBS, and streptavidin-AF647 conjugate (purchased from Biosun, catalog number bs-0437P-AF647, final concentration of 1 μg / mL) was added and incubated at room temperature for 30 min.
[0098] (4) After incubation, wash the cells three times with PBS solution.
[0099] (5) Using BD Accuri TM The detection was performed using C6 Plus flow cytometer.
[0100] 4. Detect ZHER-βGal / gFQM-biotin or ZHER-βGal / gFMeQM-biotin to selectively label HER2-positive cells.
[0101] (1) Transduction of WT MDA cells or HER2 + DMEM medium containing PBS or βGal (final concentration of 2 μg / mL) or ZHER-βGal (final concentration of 2 μg / mL) was added to MDA cells and incubated at room temperature for 30 min.
[0102] (2) After incubation, remove the culture medium and wash three times with PBS.
[0103] (3) DMEM medium containing gFQM-biotin or gFMeQM-biotin (final concentration of 10 μM) was added to the cells and labeled at 37°C for 10 min.
[0104] (4) After labeling, the culture medium was removed and the cells were washed three times with PBS solution.
[0105] (5) Add trypsin at a final concentration of 0.25% to the labeled co-culture system and incubate at 37°C for 5 min. Aspirate the trypsin and add DMEM medium to terminate digestion.
[0106] (6) Resuspend the cells in PBS containing streptavidin-AF647 conjugate (final concentration: 1 μg / mL) and incubate at 37°C for 30 min.
[0107] (7) After incubation, wash three times with PBS solution.
[0108] (8) Using BD Accuri TM The detection was performed using C6 Plus flow cytometer.
[0109] The design and characterization results of the QMID probe are shown in Figure 3 As shown. (A) Labeling mechanism of enzyme-activated QMs for cell-scale proximity labeling. (B) Chemical formulas of gFQM-biotin and gFMeQM-biotin. (C) LC-MS analysis of enzymatic activation of gFQM-biotin and gFMeQM-biotin mediated by βGal. (D) Immunoblot characterization of labeling of HEK293T cell lysates by gFQM-biotin and gFMeQM-biotin in the presence or absence of βGal. (E) Flow cytometric characterization of labeling of HEK293T cells by gFQM-biotin and gFMeQM-biotin in the presence or absence of βGal. (F) Detection of ZHER-βGal selectively labeling HER2+ cells using ONPG (the experimental procedure is as follows: HER2 positive or negative cells were cultured in a 96-well plate, and DMEM medium containing βGal, ZHER-βGal or PBS at a final concentration of 400 ng / mL was added, and incubated at 37°C for 30 min. The medium was then aspirated and the cells were washed three times with PBS. Then 0.1 mg / mL ONPG was added to the cells and incubated at 37°C for 2 h. Subsequently, the supernatant was transferred to a new 96-well plate, and the absorbance of the solution at 420 nm was read using a microplate reader. This experiment shows that ZHER-βGal can target HER2-positive cells and display active β-galactosidase on their surface). (G) Effect of gFQM-biotin and gFMeQM-biotin on HER2 cells pre-incubated with PBS / βGal / ZHER-βGal. + Flow cytometric characterization of markers of WT / WT MDA cells.
[0110] Example 4: QMID is used for cell proximity labeling in cultured cell systems
[0111] 1. Cell suspension labeling
[0112] (1) HER2 + Trypsin was added to MDA cells and WT MDA cells at a final concentration of 0.25% and incubated at 37°C for 5 min. The trypsin was removed by aspiration and DMEM medium was added to terminate the digestion.
[0113] (2) HER2 + MDA cells were resuspended in PBS solution, ZHER-βGal (final concentration was 2 μg / mL) was added, and incubated at 37°C with shaking for 30 min.
[0114] (3) After incubation, wash three times with PBS solution.
[0115] (4) After incubation, HER2 + MDA cells and WT MDA cells were resuspended in PBS at a ratio of 1:20, and gFQM-biotin or gFMeQM-biotin (final concentration of 10 μM) was added and labeled at 37°C for 10 min.
[0116] (5) After labeling, wash three times with PBS solution.
[0117] (6) Resuspend the cells in PBS, add streptavidin-AF647 conjugate (final concentration 1 μg / mL), and incubate at 37°C for 30 min.
[0118] (7) After incubation, wash three times with PBS solution.
[0119] (8) Using BD Accuri TM The detection was performed using C6 Plus flow cytometer.
[0120] 2. Labeling of adherent cells
[0121] (1) HER2 + MDA cells and WT MDA cells were co-cultured at a ratio of 1:20.
[0122] (2) DMEM medium containing ZHER-βGal (final concentration of 2 μg / mL) was added to the co-culture system and incubated at 37°C for 30 min.
[0123] (3) After incubation, remove the culture medium and wash the cells three times with PBS solution.
[0124] (4) Culture medium containing gFQM-biotin or gFMeQM-biotin (final concentration of 10 μM) was added to the co-culture system and labeled at 37°C for 10 min.
[0125] (5) After labeling, remove the culture medium and wash three times with PBS solution. If confocal fluorescence imaging analysis is performed, perform steps (6)-(10); if flow cytometry analysis is performed, perform steps (11)-(14).
[0126] (6) Add PBS containing streptavidin-AF647 conjugate (final concentration of 1 μg / mL) to the labeled co-culture system and incubate at 37°C for 30 min.
[0127] (7) After the incubation, remove the solution and wash three times with PBS solution.
[0128] (8) Add PBS solution containing Hoechst33342 (purchased from Solarbio, product number C0031, final concentration of 5 μg / mL) to the co-culture system and incubate at 37°C for 20 min.
[0129] (9) After the incubation, remove the solution and wash three times with PBS solution.
[0130] (10) The co-culture system was imaged using a Zeiss LSM 700 laser scanning confocal microscope.
[0131] (11) Add trypsin at a final concentration of 0.25% to the labeled co-culture system and incubate at 37°C for 5 min. Aspirate the trypsin and add DMEM medium to terminate digestion.
[0132] (12) The cells were resuspended in PBS containing streptavidin-AF647 conjugate (final concentration: 1 μg / mL) and incubated at 37°C for 30 min.
[0133] (13) After incubation, wash three times with PBS solution.
[0134] (14) Using BD Accuri TM The detection was performed using C6 Plus flow cytometer.
[0135] Results Figure 4 (A) QMID labeling process in cell suspension. (B) Effects of gFQM-biotin and gFMeQM-biotin on HER2 cells with or without prior incubation with ZHER-βGal + Flow cytometric characterization of the mixed suspension of MDA cells and WT MDA cells. (C,D) gFQM-biotin (C) and gFMeQM-biotin (D) for HER2 + Confocal imaging of the co-culture system of MDA cells and WT MDA cells using QMID labeling. Scale bar, 20 μm. (E, F) Effects of gFQM-biotin (E) and gFMeQM-biotin (F) on HER2 + The co-culture system of MDA cells and WT MDA cells was characterized by flow cytometry using QMID labeling.
[0136] Example 5: QMID for cell proximity labeling in mouse tissue
[0137] 1) 8-week-old C57BL / 6 mice were anesthetized with 5% isoflurane and then killed. The spleens of the mice were removed, embedded in 2% agarose and sliced using a Leica VT1200 vibratome to obtain vibratome slices with a thickness of about 100 μm, which were placed in cold HBSS.
[0138] 2) Place the slices in PBS, add CD16 / 32 antibody (purchased from BioLegend, catalog number 156603, used at a dilution of 1:1000), immerse the slices, and block at room temperature for 10 minutes.
[0139] 3) Aspirate the solution, add PBS solution containing antibody (CD4 / CD8a)-biotin conjugate (purchased from BioLegend, catalog numbers 100507 and 100703, respectively, used at a dilution of 1:1000) to the slices, immerse the slices, and incubate at 4°C for 1 hour.
[0140] 4) Aspirate the solution and wash the sections three times with PBS.
[0141] 5) Add PBS containing streptavidin-βGal conjugate (purchased from Abcam, catalog number ab279316, used at a dilution of 1:1000) and streptavidin-AF488 conjugate (purchased from Biosun, catalog number bs-0437P-AF488, final concentration of 1 μg / mL) to the slices, immerse the slices, and incubate at 4°C for 30 min.
[0142] 6) Aspirate the solution and wash the sections three times with PBS.
[0143] 7) Add PBS containing gFQM-biotin or gFMeQM-biotin (final concentration of 10 μM) to the slices, immerse the slices, and incubate at 37° C. for 10 min.
[0144] 8) Aspirate the solution and wash the slices 3 times with PBS. If confocal fluorescence imaging analysis is performed, perform steps 9-15; if flow cytometry analysis is performed, perform steps 16-19.
[0145] 9) Add 4% paraformaldehyde solution to the slices, immerse the slices, and fix at room temperature for 30 minutes.
[0146] 10) Aspirate the solution and wash the sections three times with PBS.
[0147] 11) Add PBS containing streptavidin-AF647 conjugate (final concentration of 1 μg / mL) to the slices, immerse the slices, and incubate at room temperature for 30 minutes.
[0148] 12) Aspirate the solution and wash the sections three times with PBS.
[0149] 13) Add PBS containing Hoechst 33342 (final concentration 10 μg / mL) to the slices and incubate at room temperature for 30 min.
[0150] 14) Aspirate the solution and wash three times with PBS.
[0151] 15) The co-culture system was imaged using a Zeiss LSM 700 laser scanning confocal microscope.
[0152] 16) The slices were mechanically digested to obtain a cell suspension, which was filtered through a 70 μm cell sieve and washed once with PBS.
[0153] 17) Resuspend the cells in PBS containing streptavidin-AF647 conjugate (final concentration 1 μg / mL) and incubate at room temperature for 30 min.
[0154] 18) After incubation, wash three times with PBS solution.
[0155] 19) Using BD Accuri TM The detection was performed using C6 Plus flow cytometer.
[0156] The results are as follows Figure 5 As shown. (A) Schematic diagram of QMID labeling of mouse spleen sections using a combination of primary antibody-biotin conjugate and streptavidin-βGal conjugate. (B,C) Confocal imaging characterization of CD8+T cells (B) and CD4+T cells (C) neighboring cells labeled by QMID. (D) Flow cytometry characterization of CD8+T cells and CD4+T cells neighboring cells labeled by QMID.
[0157] Example 6: QMID analysis of neighboring cell maps of mouse spleen T cells
[0158] According to steps 1-8 and 16-19 in Example 5, the cells adjacent to CD4+ and CD8+ T cells in mouse spleen sections were labeled.
[0159] The cells adjacent to CD4+ and CD8+ T cells were sorted using BD FACS AriaIII flow cytometry and then subjected to single-cell RNA sequencing. The sequencing platform was selected from Syngenomics, and each cell was calculated based on 30M sequencing data.
[0160] The sequencing results were analyzed using the Seurat package and the results are shown in the attached Figure 6 .
[0161] Results Figure 6, (A) UMAP analysis of cells adjacent to CD8+T cells and CD4+T cells in mouse spleen sections. (B) Stacked bar graph of normalized relative proportions of different types of cells. (C) Heat map of genes with significantly different expression levels in mature dendritic cells adjacent to CD8+T cells and CD4+T cells. (D) GSEA showed that lipid degradation processes and WNT signaling pathways were significantly upregulated in mature dendritic cells adjacent to CD8+T cells.
[0162] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. A cell labeling method, which is to covalently label cells with a methylene benzoquinone intermediate generated by an enzyme-activated methylene benzoquinone probe to achieve in situ labeling of cells, namely, the QMID method.
2. The method according to claim 1, Features: The methylene benzoquinone intermediate covalently links to nucleophilic residues of cell surface proteins; The cells are cells adjacent to a specific cell type; The methylene benzoquinone probe has the following structural units:
3. The method according to claim 1 or 2, Features: The methylene benzoquinone probe has a structural formula as shown in Formula I: In Formula I, R 1 Indicates H, C 1 -C 3 alkyl; R 2 Selected from: β-galactose residues, glutamic acid residues, sialic acid residues, fucose residues; Biotin indicates The enzyme is used to remove the substituent R in the methylene benzoquinone probe 2 ; The enzyme is based on the substituent R in the methylene benzoquinone probe 2 choose; The enzyme is also linked to an antibody that binds to a specific cell type for targeting the specific cell type.
4. The method according to claim 1 or 2, Features: The methylene benzoquinone probe has R 2 is a β-galactose residue and the enzyme is β-galactosidase.
5. The method according to claim 1 or 2, Features: The method further comprises the following steps: using a flow cytometer to separate the labeled cells and then combining them with RNA sequencing or single-cell RNA sequencing to achieve a comprehensive analysis of the gene expression of neighboring cells of specific cells.
6. Use of the QMID method according to any one of claims 1 to 5 in proximity labeling of cells not in direct contact and proximity labeling of cells in tissues.
7. The methylene benzoquinone probe represented by formula I in claim 3.
8. Use of the methylene benzoquinone probe according to claim 7 in a QMID method.
9. A method for analyzing gene expression of neighboring cells of a specific cell, comprising the following steps: 1) Incubate the cell system to be analyzed with the enzyme to modify the enzyme on the surface of specific cells; 2) adding the methylene benzoquinone probe according to claim 7 to the system obtained in step 1) to complete labeling; 3) Analyze cells using flow cytometry or confocal fluorescence imaging to confirm the labeling effect of neighboring cells.
10. The method according to claim 9, Features: The analysis is: using FISH or immunofluorescence to target specific RNA and proteins, and using flow cytometry to analyze gene expression in neighboring cells.
